what are the optimal doses of cefuroxime for cirrhotic patients?

what are the optimal doses of cefuroxime for cirrhotic patients? - cefuroxime in cirrhotic patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-003349-41-BE

Enrollment

Registered

2013-09-12

Start date

2013-10-03

Completion date

Unknown

Last updated

2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhotic patients with infection requiring treatment with cefuroxime MedDRA version: 16.0 Level: LLT Classification code 10024678 Term: Liver failure System Organ Class: 100000004871

Interventions

Trade Name: Zinacef Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: Zinacef Current Sponsor code: Zinacef Other descriptive name: CEFUROXIME SODIUM STERILE Concentration unit

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients aged more than 18 year-old with cirrhosis child A (=65 years) yes F.1.3.1 Number of subjects for this age range 10

Exclusion criteria

Exclusion criteria: patients less than 18 year-old, pregnant women, patients with body mass index 30 kg/m². Patients infected with HIC and hepatitis C

Design outcomes

Primary

Measure	Time frame
Main Objective: To evaluate the pharmacokinetics of cefuroxime in cirrhotic patients;Secondary Objective: not applicable;Primary end point(s): Study of pharmacokinetic parameters;Timepoint(s) of evaluation of this end point: NA	—

Secondary

Measure	Time frame
Secondary end point(s): NA;Timepoint(s) of evaluation of this end point: NA	—

Countries

Belgium

Contacts

Public ContactMaya Hites

Erasme Hospital

maya.hites@erasme.ulb.ac.be3225555579

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026